Clinical Trials Directory

Trials / Completed

CompletedNCT02085993

Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training

A Cross-sectional Study of Patients With Immune Thrombocytopenic Purpura and Caregivers to Estimate the Proportion Who Administer Romiplostim Correctly After Receipt of Home Administration Training Materials

Status
Completed
Phase
Study type
Observational
Enrollment
41 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Cross-sectional study, observation made by healthcare professionals of subjects or caregivers, administering romiplostim at their first standard-of-care visit 4 weeks after training with the home administration training pack. Further observations can also be recorded in the study if made within 16 weeks of enrolment. Data will be collected from the subjects' dose diary at their first standard of care visit to ensure there were no problems with administration while not at the clinic.

Detailed description

This cross-sectional study involves direct observation by a healthcare professional of a series of subjects and caregivers in the act of administering romiplostim at their first standard-of-care visit occurring 4 weeks after training with the HAT pack. Further observations, if they occur, will also be recorded in the study if made within 16 weeks of enrolment. (Additional observations are voluntary and are not required for study participation; they occur only if the healthcare professional requests them.) Additionally, data will be collected from the subjects' dose diary at the first standard of care visit to ensure there were no problems with administration while not at the clinic.

Conditions

Timeline

Start date
2014-07-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2014-03-13
Last updated
2015-12-22

Locations

22 sites across 8 countries: Austria, Belgium, France, Germany, Greece, Netherlands, Spain, United Kingdom

Source: ClinicalTrials.gov record NCT02085993. Inclusion in this directory is not an endorsement.